Reduction of human T-cell leukemia virus type 1 (HTLV-1) proviral loads in rats orally infected with HTLV-1 by reimmunization with HTLV-1-infected cells

Journal of Virology

Volumn 80, Issue 15, 2006, Pages 7375-7381

  Komori, Kazuya ^a   Hasegawa, Atsuhiko ^a,b   Kurihara, Kiyoshi ^a   Honda, Takayuki ^a   Yokozeki, Hiroo ^a   Masuda, Takao ^a   Kannagi, Mari ^a,c  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; MITOMYCIN C;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL TRANSFORMATION; CELLULAR IMMUNITY; CONTACT ALLERGY; CONTROLLED STUDY; FEMALE; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNIZATION; IN VIVO STUDY; MIXED LYMPHOCYTE REACTION; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROVIRUS; RAT; SPASTIC PARAPLEGIA; SPINAL CORD DISEASE; SPLEEN CELL; T CELL LEUKEMIA; T LYMPHOCYTE; VIRUS LOAD;

ADMINISTRATION, ORAL; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELLS, CULTURED; FEMALE; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; IMMUNIZATION; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; MITOMYCIN; PROVIRUSES; RATS; RATS, INBRED ACI; RATS, INBRED F344; SKIN; SPLEEN; SPLENECTOMY; T-LYMPHOCYTES; VIRAL LOAD;

HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 33746190723     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00230-06     Document Type: Article

References (53)

1. Arnulf, B., M. Thorel, Y. Poirot, R. Tamouza, E. Boulanger, A. Jaccard, E. Oksenhendler, O. Hermine, and C. Pique. 2004. Loss of the ex vivo but not the reinducihle CD8+ T-cell response to Tax in human T-cell leukemia virus type 1-infectcd patients with adult T-cell leukemia/lymphoma. Leukemia 18:126-132.
2. Cavrois, M., A. Gessain, S. Wain-Hobson, and E. Wattel. 1996. Proliferation of HTLV-1 infected circulating cells in vivo in all asymptomatic carriers and patients with TSP/HAM. Oncogcne 12:2419-2423.
3. Chen, S., N. Ishii, S. Ine, S. Ikeda, T. Fujimura, L. C. Ndhlovu, P. Soroosh, K. Tada, H. Harigae, J. Kameoka, N. Kasai, T. Sasaki, and K. Sugamura. 2006. Regulatory T cell-like activity of Foxp3+ adult T cell leukemia cells. Int. Immunol. 18:269-277.
4. Faria, A. M., and H. L. Weiner. 2005. Oral tolerance. Immunol. Rev. 206: 232-259.
5. Gessain, A., F. Barin, J. C. Vernant, O. Gout, L. Maurs, A. Calender, and G. de The. 1985. Antibodies to human T-lymphotropic virus type-1 in patients with tropical spastic paraparesis. Lancet ii:407-410.
6. Hakata, Y., M. Yamada, and H. Shida. 2001. Rat CRM1 is responsible for the poor activity of human T-cell leukemia virus type 1 Rex protein in rat cells. J. Virol. 75:11515-11525.
7. Hanabuchi, S., T. Ohashi, Y. Koya, H. Kato, A. Hasegawa, F. Takemura, T. Masuda, and M. Kannagi. 2001. Regression of human T-cell leukemia virus type I (HTLV-1)-associated lymphomas in a rat model: peptide-induced T-cell immunity. J. Natl. Cancer Inst. 93:1775-1783.
8. Hasegawa, A., T. Ohashi, S. Hanabuchi, H. Kato, F. Takemura, T. Masuda, and M. Kannagi. 2003. Expansion of human T-cell leukemia virus type I (HTLV-1) reservoir in orally infected rats: inverse correlation with HTLV-1-specific cellular immune response. J. Virol. 77:2956-2963.
9. Hino, S., S. Katamine, H. Miyata, Y. Tsuji, T. Yamabe, and T. Miyamoto. 1996. Primary prevention of HTLV-1 in Japan. J. Acquir. Immune. Defie. Syndr. Hum. Retrovirol. 13(Suppl. 1):S199-S203.
10. Hino, S., K. Yamaguchi, S. Katamine, H. Sugiyama, T. Amagasaki, K. Kinoshita, Y. Yoshida, H. Doi, Y. Tsuji, and T. Miyamoto. 1985. Mother-10-child transmission of human T-cell leukemia virus type-1. Jpn. J. Cancer Res. 76:474-480.
11. Hinuma, Y., Y. Gotoh, K. Sugamura, K. Nagata, T. Goto, M. Nakai, N. Kamada, T. Matsumoto, and K. Kinoshita. 1982. A retrovirus associated with human adult T-cell leukemia: in vitro activation. Gann 73:341-344.
12. Hinuma, Y., K. Nagata, M. Hanaoka, M. Nakai, T. Matsumoto, K. I. Kinoshita, S. Shirakawa, and I. Miyoshi. 1981. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc. Natl. Acad. Sci. USA 78:6476-6480.
13. Hisada, M., A. Okayama, D. Spiegelman, N. E. Mueller, and S. O. Stuver. 2001. Sex-specific mortality from adull T-cell leukemia among carriers of human T-lymphotropic virus type I. Int. J. Cancer 91:497-499.
14. Hisada, M., A. Okayama, N. Tachibana, S. O. Stuver, D. L. Spiegelman, H. Tsuhouchi, and N. E. Mueller. 1998. Predictors of level of circulating abnormal lymphocytes among human T-lymphotropic virus type I carriers in Japan. Int. J. Cancer 77:188-192.
15. Igakura, T., J. C. Stinchcombe, P. K. Goon, G. P. Taylor, J. N. Weber, G. M. Grifliths, Y. Tanaka, M. Osame, and C. R. Bangham. 2003. Spread of HTLV-1 between lymphocytes by virus-induced polarization of the cytoskeleton. Science 299:1713-1716.
16. + cytotoxic T lymphocytes specific for HTLV-1 pX in patients with HTLV-1 associated neurological disease. Nature 348:245-248.
17. Jeang, K. T. 2001. Functional activities of the human T-cell leukemia virus type 1 Tax oncoprotein: cellular signaling through NF-κB. Cytokine Growth Factor Rev. 12:207-217.
18. + cytotoxic T cells directed against HTLV-1-infected cells. Int. Immunol. 3:761-767.
19. Kannagi, M., S. Matsushita, and S. Harada. 1993. Expression of the target antigen for cytotoxic T lymphocytes on adult T-cell-leukemia cells. Int. J. Cancer 54:582-588.
20. Kannagi, M., K. Sugamura, K. Kinoshita, H. Uchino, and Y. Hinuma. 1984. Specific cytolysis of fresh tumor cells by an autologous killer T-cell line derived from an adult T-cell leukemia/lymphoma patient. J. Immunol. 133: 1037-1041.
21. Kannagi, M., K. Sugamura, H. Sato, K. Okochi, H. Uchino, and Y. Hinuma. 1983. Establishment of human cytotoxic T-cell lines specific for human adult T-cell leukemia virus-bearing cells. J. Immunol. 130:2942-2946.
22. Kato, H., Y. Koya, T. Ohashi, S. Hanabuchi, F. Takemura, M. Fujii, H. Tsujimoto, A. Hasegawa, and M. Kannagi. 1998. Oral administration of human T-cell leukemia virus type I induces immune unresponsiveness with persistent infection in adult rats. J. Virol. 72:7289-7293.
23. + T cell-mediated contact hypersensitivity. J. Exp. Med. 189:779-786.
24. Kondo, T., H. Kono, N. Miyamoto, R. Yoshida, H. Toki, I. Matsumoto, M. Hara, H. Inoue, A. Inatsuki, T. Funatsu, et al. 1989. Age- and sex-specific cumulative rate and risk of ATLL for HTLV-1 carriers. Int. J. Cancer 43: 1061-1064.
25. Koya, Y., T. Ohashi, H. Kato, S. Hanabuchi, T. Tsukahara, F. Takemura, K. Etoh, M. Matsuoka, M. Fujii, and M. Kannagi. 1999. Establishment of a seronegative human T-cell leukemia virus type 1 (HTLV-1) carrier state in rats inoculated with a syngeneic HTLV-1-immortalized T-cell line preferentially expressing Tax. J. Virol. 73:6436-6443.
26. + lymphocytes correlate with the proviral load in peripheral blood of infected individuals. J. Neuroimmunol. 102:208-215.
27. Kurihara, K., N. Harashima, S. Hanabuchi, M. Masuda, A. Utsunomiya, R. Tanosaki, M. Tomonaga, T. Ohashi, A. Hasegawa, T. Masuda, J. Okamura, Y. Tanaka, and M. Kannagi. 2005. Potential immunogenicity of adult T-cell leukemia cells in vivo. Int. J. Cancer 114:257-267.
28. Kuroda, Y., and H. Takashima. 1990. Impairment of cell-mediated immune responses in HTLV-1-associated myelopathy. J. Neurol. Sci. 100:211-216.
29. Lal, R. B., D. L. Rudolph, C. S. Dezzutti, P. S. Linsley, and H. E. Prince. 1996. Costimulatory effects of T cell proliferation during infection with human T lymphotropic virus types I and II are mediated through CD80 and CD86 ligands. J. Immunol. 157:1288-1296.
30. Manns, A., F. R. Cleghorn, R. T. Falk, B. Hanchard, E. S. Jaffe, C. Bartholomew, P. Hartge, J. Benichou, and W. A. Blattner. 1993. Role of HTLV-1 in development of non-Hodgkin lymphoma in Jamaica and Trinidad and Tobago. The HTLV Lymphoma Study Group. Lancet 342:1447-1450.
31. Marie, J. C., J. Kehren, M. C. Trescol-Biemont, A. Evlashev, H. Valentin, T. Walzer, R. Tedone, B. Loveland, J. F. Nicolas, C. Rabourdin-Combe, and B. Horvat. 2001. Mechanism of measles virus-induced suppression of inflammatory immune responses. Immunity 14:69-79.
32. Matsuzaki, T., M. Nakagawa, M. Nagai, K. Usuku, I. Higuchi, K. Arimura, H. Kubota, S. Izumo, S. Akiba, and M. Osame. 2001. HTLV-1 proviral load correlates with progression of motor disability in HAM/TSP: analysis of 239 HAM/TSP patients including 64 patients followed up for 10 years. J. Neurovirol. 7:228-234.
33. Murai, K., N. Tachihana, S. Shioiri, E. Shishime, A. Okayama, J. Ishizaki, K. Tsuda, and N. Mueller. 1990. Suppression of delayed-type hypersensitivity to PPD and PHA in elderly HTLV-1 carriers. J. Acquir. Immune. Defic. Syndr. 3:1006-1009.
34. Murphy, E. L., V. Wu, H. E. Ownby, J. W. Smith, R. K. Ruedy, R. A. Thomson, D. I. Ameti, D. J. Wright, and G. J. Nemo. 2001. Delayed hypersensitivity skin testing to mumps and Candida albicans antigens is normal in middle-aged HTLV-1- and-11-infected U.S. cohorts. AIDS Res. Hum. Retrovir. 17:1273-1277.
35. Nowak, M. A., and C. R. Bangham. 1996. Population dynamics of immune responses to persistent viruses. Science 272:74-79.
36. Ohashi, T., S. Hanahuchi, H. Kato, H. Tateno, F. Takemura, T. Tsukahara, Y. Koya, A. Hasegawa, T. Masuda, and M. Kannagi. 2000. Prevention of adult T-cell leukemia-like lymphoproliferative disease in rats by adoptively transferred T cells from a donor immunized with human T-cell leukemia virus type 1 Tax-coding DNA vaccine. J. Virol. 74:9610-9616.
37. Okayama, A., S. Stuver, M. Matsuoka, J. Ishizaki, G. Tanaka, Y. Kubuki, N. Mueller, C. C. Hsieh, N. Tachibana, and H. Tsubouchi. 2004. Role of HTLV-1 proviral DNA load and clonality in the development of adult T-cell leukemia/lymphoma in asymptomatic carriers. Int. J. Cancer 110:621-625.
38. Osame, M., K. Usuku, S. Izumo, N. Ijichi, H. Amitani, A. Igata, M. Matsumoto, and M. Tara. 1986. HTLV-1 associated myelopathy. a new clinical entity. Lancet i:1031-1032.
39. Pankow, R., H. Durkop, U. Latza, H. Krause, U. Kunzendorf, T. Pohl, and S. Bulfone-Paus. 2000. The HTLV-1 tax protein transcriptionally modulates OX40 antigen expression. J. Immunol. 165:263-270.
40. Parker, C. E., S. Daenke, S. Nightingale, and C. R. Bangham. 1992. Activated, HTLV-1-specific cytotoxic T-lymphocytes arc found in healthy seropositives as well as in patients with tropical spastic paraparesis. Virology 188:628-636.
41. Poiesz, B. J., F. W. Ruscetti, A. F. Gazdar, P. A. Bunn, J. D. Minna, and R. C. Gallo. 1980. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci. USA 77:7415-7419.
42. Skoglund, C., and A. Scheynius. 1990. Effects of interferon-gamma treatment on the cutaneous DTH reaction in rats. Arch. Dermatol. Res. 282:318-324.
43. + cells are suppressed by measles virus infection during delayed type hypersensitivity reaction. Viral, Immunol. 17:604-608.
44. Tajima, K., et al. 1990. The 4th nationwide study of adult T-cell leukemia/lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features. Int. J. Cancer 45:237-243.
45. Taylor, G. P., S. E. Hall, S. Navarrete, C. A. Michie, R. Davis, A. D. Witkover, M. Rossor, M. A. Nowak, P. Rudge, E. Matutes, C. R. Bangham, and J. N. Weber. 1999. Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number. T-cell phenotype. and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy. J. Virol. 73:10289-10295.
46. Uchiyama, T. 1997. Human T-cell leukemia virus type 1 (HTLV-1) and human diseases. Annu. Rev. Immunol. 15:15-37.
47. Vaz, N., A. M. Faria, B. A. Verdolin, and C. R. Carvalho. 1997. Immaturity, ageing and oral tolerance. Scand. J. Immunol. 46:225-229.
48. + lymphocytes distinguishes between individuals with a high or low proviral load of human T-cell lymphotropic virus type 1. J. Immunol. 173:5121-5129.
49. Walker, D. B., W. C. Williams, C. B. Copeland, and R. J. Smialowicz. 2004. Persistent suppression of contact hypersensitivity, and altered T-cell parameters in F344 rats exposed perinatally to 2,3,7,8-tetrachlorodibenzo-p- dioxin (TCDD). Toxicology 197:57-66.
50. Welles, S. L., N. Tachibana, A. Okayama, S. Shioiri, S. Ishiliara, K. Murai, and N. E. Mueller. 1994. Decreased reactivity to PPD among HTLV-1 carriers in relation to virus and hematologic status. Int. J. Cancer 56:337-340.
51. Wodarz, D., S. E. Hall, K. Usuku, M. Osame, G. S. Ogg, A. J. McMichael, M. A. Nowak, and C. R. Bangham. 2001. Cytotoxic T-cell abundance and virus load in human immunodeficiency virus type I and human T-cell leukaemia virus type 1. Proc. Biol. Sci. 268:1215-1221.
52. Yoshida, M. 2001. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu. Rev. Immunol. 19:475-496.
53. Yoshida, M., M. Seiki, K. Yamaguehi, and K. Takatsuki. 1984. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc. Natl. Acad. Sci. USA 81:2534-2537.